Rate My Professor Anders Sönnerborg

Sönnerborg leads the research group on translational research on human microbial infections and their consequences, studying pathogenesis, treatment, and control of viral and bacterial infections, particularly HIV-1. His investigations cover HIV reservoirs and cure strategies, antiretroviral therapy optimization, drug resistance, molecular epidemiology, microbiome influences on HIV-1 and SARS-CoV-2, antiviral development, and co-infections such as hepatitis C and tuberculosis/HIV. Key publications include "HIV-1 sub-subtype A6 remains susceptible to second-generation integrase inhibitors with limited emergence of resistance in vitro" (Open Forum Infectious Diseases, 2026), "Linking gut microbiome to HIV-1 reservoir size in people living with HIV" (Gut Pathogens, 2026), "Sweden surpasses the UNAIDS 95-95-95 target: estimating HIV-1 incidence, 2003 to 2022" (Eurosurveillance, 2024), "Prophylaxis and treatment of HIV infection in pregnancy, Swedish guidelines 2024" (Infectious Diseases, 2024), and "Long-term HIV-1 remission achieved through allogeneic hematopoietic stem cell transplantation" (Nature Microbiology, 2026). He supervises doctoral theses, secures grants from the Swedish Research Council, and contributes to cohorts like InfCareHIV, EuResist, and EuCARE, as well as national treatment guidelines.